Background: Data on long-term safety of filgrastim administration in normal PBPC donors are scarce. In the view of the known biologic activity of filgrastim, the main theoretical risk is believed to be the possible, late development of acute or chronic leukemia. Material and Methods: We conducted a survey of the PBPC donors enrolled and registered in the PBPC collection protocol at our institution between 1994 and 1998. This time period was selected to ensure adequate long-term follow-up. The study was approved by the Intsitutional Review Board and the participants provided informed consent. A total of 396 PBPC donors were included in the database. They underwent filgrastim mobilization (for 3-5 days on average) and PBPC apheresis. The donors were interviewed by telephone between December 1998 and February 2000. Fifty-three donors were excluded from the survey (forty-nine were not living in the US, three had blank records/no donor name available, and one person did not actually donate). Results: Of the remaining 343 donors, 281 (82%) were interviewed. The reasons for the lack of interview (n=62) were: no current contact information available n=36 (10%), declined n=10 (3%), no response despite multiple contacts n=14 (4%), and two had died (one suicide, one grand mal seizure, both seemingly unrelated to the donation). The mean age at donation was 44 years (range 5 -77), 47% male and 53% female. Seventy-six percent were Caucasian, 17% were Hispanic, 5% were AficanAmerican, and 1% other ethnicities. The donor was usually the sibling of the recipient (96%), with 4% being some other blood relative. The median follow-up after PBPC donation was 39 months (range 7-80), 99% had at least one year of follow-up. Six donors had donated stem cells at other institutions. At the time of the interview none of the donors had been diagnosed with acute or chronic leukemia. Conclusion: Although the sample size is small and the follow-up is limited, these data suggest that brief (3-5 days) exposure to filgrastim during PBPC donation is not associated with any obvious or striking long-term (3-4 years) risk for the development of leukemia.
Background: Data on long-term safety of filgrastim administration in normal PBPC donors are scarce. In the view of the known biologic activity of filgrastim, the main theoretical risk is believed to be the possible, late development of acute or chronic leukemia. Material and Methods: We conducted a survey of the PBPC donors enrolled and registered in the PBPC collection protocol at our institution between 1994 and 1998. This time period was selected to ensure adequate long-term follow-up. The study was approved by the Intsitutional Review Board and the participants provided informed consent. A total of 396 PBPC donors were included in the database. They underwent filgrastim mobilization (for 3-5 days on average) and PBPC apheresis. The donors were interviewed by telephone between December 1998 and February 2000. Fifty-three donors were excluded from the survey (forty-nine were not living in the US, three had blank records/no donor name available, and one person did not actually donate). Results: Of the remaining 343 donors, 281 (82%) were interviewed. The reasons for the lack of interview (n=62) were: no current contact information available n=36 (10%), declined n=10 (3%), no response despite multiple contacts n=14 (4%), and two had died (one suicide, one grand mal seizure, both seemingly unrelated to the donation). The mean age at donation was 44 years (range 5 -77), 47% male and 53% female. Seventy-six percent were Caucasian, 17% were Hispanic, 5% were AficanAmerican, and 1% other ethnicities. The donor was usually the sibling of the recipient (96%), with 4% being some other blood relative. The median follow-up after PBPC donation was 39 months (range 7-80), 99% had at least one year of follow-up. Six donors had donated stem cells at other institutions. At the time of the interview none of the donors had been diagnosed with acute or chronic leukemia. Conclusion: Although the sample size is small and the follow-up is limited, these data suggest that brief (3-5 days) exposure to filgrastim during PBPC donation is not associated with any obvious or striking long-term (3-4 years) risk for the development of leukemia.
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Continuous Ca2+ supplementation during stem cell apheresis: a prospective trial C. Buchta, M. Macher, P. Höcker, M. Dettke (Vienna, A) Hypocalcaemia related symptoms are common side effects during stem cell apheresis. We performed a prospective, randomized placebo controlled double-blinded study in order to analyze the effect of i.v. Ca2+ supplementation on serum electrolytes and the appearance of adverse reactions related to citrate administration during a standardized large volume (4x whole body blood volume) stem cell apheresis. The study population consisted on 29 patients with various forms of solid or hematological malignancies. Patients received either Ca-gluconat (40 mMol dissolved in 500 mL NaCl; 15 pts.) or placebo (NaCl, 14 pts.), supplementation was applied continuously at a constant flow rate until completion of the apheresis procedure. Continuous Ca2+ support reduced citrateinduced decrease in ionized serum Ca2+ (iCa; delta iCa before and after pheresis = -9.16 % vs.-22.53% in the placebo group) while slightly increasing the extraction of Mg2+ (delta Mg2+ = -19.27% compared to -10.96% in the control group). Other serum electrolytes (Na+, K+) were not affected by continuous Ca supplementation. Increase in the level of parathyroid hormone was less pronounced in the test group (+13.7%) compared to controls (+188.3%). Ca support led to reduced frequency of adverse reactions (p<0.001), and patients receiving Ca support required less additionally intervention compared to controls (p<0.05). In addition, patients receiving Ca support felt less discomfort compared to controls, as assessed by a standardized discomfort scale. Continuous Ca supplementation had no influence on the stem cell product collected. We conclude that i.v. Ca2+ supplementation at a controlled flow rate is an effective means to reduce citrate-related changes in serum iCa and the appearance of adverse symptoms during stem cell apheresis. Continuous Ca supplementation should therefore be recommended as an standard treatment in patients undergoing large volume stem cell apheresis.
Supportive Care
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Home-based autologous stem cell transplantation: a singlecenter experience F. Fernández-Avilés, E. Carreras, C. Gallego, A. Hernando, S. Segura, L. García, M. Rovira, C. Martínez, A. Urbano-Ispizua, E. Gómez, M. Valverde, E. Montserrat (Barcelona, E) Background: To improve the patient's quality of life and reduce hospital expenses there is a trend to perform ASCT on a outpatient basis. This, however, has the disadvantage of overloading Day Care Unit facilities. For that reason, we have analysed the feasibility of home-based ASCT. Patients and methods: At home ASCT (since day +1) was offered to all patients with a good performance status, a travelling time to the hospital of less than 45 minutes, and a caregiver available 24 h a day able to understand and to carry out basic caring measures. Inpatients and at home ASCT received the same supportive care in terms of transfusions, G -CSF, dietary recommendations, and prophylactic oral antibiotics. At home patients received prophylactic i.v. ceftriaxone once daily. An experienced nurse visited the patient once or twice daily, checked vital signs and examined him, took blood samples and administered i.v. medications. The responsible physician spoke over the telephone with the patient daily after reviewing the test results. A temperature of 38ºC was indication for going immediately to the hospital. When a complete check-up did not show neither focal infection nor data of severe sepsis and first dose of antibiotics were administered the patient could go home despite fever. Blood and platelet transfusions were administered in the day care unit. Results: During t he study period (November 2000 -September 2001 ) the overall number of ASCT performed in our unit was 56. Of those, 14 (25%), median age 48 years (range: 21-64), were managed at home. The remaining were not included into the program due to patient preference (17%), poor PS (39%), distant home (34%) and social problems (10%). All patients developed fever but only three (21%) needed hospital admission (2, 5 and 5 days). Days with fever, time to engraftment, days with G-CSF, need for transfusion and other toxicity were not different in both groups. The median (range) number of visits in the day care unit for fever or transfusions was 2 (2-4). The median (range) hospital stay (since day +1) was 0 (0-5) days for at home and 16 (1-69) for conventional ASCT (p<0.00001). A prospective hospital cost analysis showed a saving of around 6000 Euro per at home ASCT. Conclusions: These results suggest that for selected patients ASCT can be cost-effectively performed at home. Home Care Unit is supported by a grant from Schering-Plough Spain S19
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Home care for children post hematopoietic stem cell transplantation M. Miano, L. Manfredini, A. Garaventa, S. Fieramosca, R. Tanasini, M. Leimer, G. Dini (Genoa, I) The quality of life of patients who undergo HSCT is deeply affected by frequent and sometimes long periods of hospitalisation for the treatment of various complications. Many of these complications don't require continuous medical supervision and may be cared for at home. On this basis, in April 2000 a program of Home Care (HC) was activated in the Paediatric Haematology and Oncology Department of G. Gaslini Children Hospital in Genoa in order to improve the quality of life of the pts, to reduce the costs, and to improve the availability of the hospital ward for more critical pts. Patients undergone HSCT in stable non critical conditions needing i.v. therapies, parenteral nutrition administration, transfusional support, blood examinations, and central venous catheter (CVC) management, as well as children needing palliative care were considered eligible to the program. After one year of activity 16 transplanted children, aged 1-14 years (median 6 years) were treated at home. 8 and 5 out of 16 children were transplanted with unrelated or related donor bone marrow, respectively. The remaining 3 children underwent autologous HSCT. All of them needed blood tests and/or i.v. therapies including parenteral nutrition administration or blood transfusions. 5 out 14 children were early discharged and trained to use CVC at home. In 2 cases palliative cares were administered. The overall activity consisted in 419 i.v. therapies, 353 blood tests, 44 blood transfusions, 22 CVC use training, 23 total parenteral nutrition, and 177 hydratations. The median duration of the assistance for each child was 33 days (range 5-172). A median of 4 pts per week were assisted for a total of 741 days. A total of 498 accesses at home replaced 385 and 113 outpatient and in-patient days of hospitalisation. The average cost per patient given HC (74700 Euro, range 750-20,700) resulted significantly lower (p<0.001) when compared with the average cost per patient hospitalised to undergo the same procedures (219,600 Euro, range 1,750-66,300). The staying at home itself represents the incalculable advantage of this service for these children and their families. These children had the possibility to be earlier discharged and looked after at home for all the follow-up period, making the beds of the ward easier available. This report shows that HC is a feasible kind of assistance for children after HSCT, improves the quality of life of the pts and their families, and reduces the costs.
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A mixed outpatient-inpatient model for autologous bone marrow transplantation in multiple myeloma F. Morabito, M. Martino, G. Irrera, G. Console, M. Messina, M. Fujo, C. Stelitano, V. Callea, F. Nobile, P. Iacopino (Reggio Calabria, I) One hundred consecutive PBSCT were performed in 54 MM patients, 44 following a total inpatient (TIM) and 56 a mixed inpatient-oupatient model (MIOM). After VAD regimen and cyclophosfamide for stem cell collection, patients were conditioned with melphalan (Mel) 200 mg/m2. MIOM patients were obligatorily admitted at day 0 for stem cell infusion for 2 consecutive days and discharged thereafter. All patients received anti-bacterial, anti-viral and anti-fungal prophylaxis and G-CSF 5 mcg/kg/day from day +3 until neutrophil engraftment. Fifty-four patients underwent a single (29 TIM, 25 MIOM), 36 a double (12 TIM, 24 MIOM) and 10 a triple (3 TIM and 7 MIOM) PBSCT. MIOM patients were significantly older than the other group (50.9 ± 8.4 years in TIM vs 55.0 ± 6.4 in MIOM, p=0.0082). Although no difference was demonstrated in terms of stem cells infused (6.7 ± 6.4 x 106/kg in TIM vs 5.4 ± 2.5 x 106/kg in MIOM), the time for granulocyte recovery was significantly shorter in MIOM group (8.9 ± 0.7 days vs 9.4 ± 1.7, p=0.0058). The number of grade II-III mucositis was equally distributed between the two groups (38.6% in TIM vs 29.6% in MIOM), while a significantly higher number of febrile episodes was documented among TIM patients (71.1% vs 49.1%, p=0.004). As expected, the mean duration of hospitalisation was only 6 days (range) among the MIOM procedures, which was significantly shorter than the average 20 days for the TIM transplants. We defined as failure in the MIOM program when a patient was not discharged after stem cell infusion or re-admitted because of transplant-related complications. In particular, out of the 56 transplants, 4 were not discharged after stem cell infusion (mean hospital stay 15 days), 28 (50%) were never re-admitted (mean number of day-hospital admissions 9) and, finally, the remaining 24 cases were readmitted for a mean of 8.6 days of hospital stay. The most important cause of MIOM program failure was fever not manageable in the outpatient setting, followed by a reduced compliance to the MIOM program (3 cases), severe reduction of water intake (4 cases), pulmonary thromboembolic event (1 case)and renal toxicity (2 cases). One case of transplant-related death was documented in MIOM group at +12 day. In conclusion, since outpatient management and liberal hospitalisation criteria of these patients has resulted in safe conduct in MIOM transplants, MIOM can be offered to MM patients in alternative to TIM program.
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Administration of recombinant human erythropoietin before autologous stem cell transplantation significantly reduces transfusion requirement: a case-control study M. Martino, F. Morabito, G. Console, G. Irrera, G. Pucci, G. Messina, M. Fujo, E. Oliva, P. Iacopino (Reggio Calabria, I) Recipients of both allogeneic and autologous stem cell transplantation have a frequent need for red blood cell transfusions and therefore an increased risk of blood-transmitted infections. Etiology of anemia is multi-factorial, mainly due to myelosuppression after high-dose chemotherapy, though impaired erythropoietin (EPO) production and an inappropriate EPO response significantly contribute to its development. In allogeneic transplantation, randomised trials have demonstrated a decrease in red cell transfusions in patients treated with recombinant human (rHu)EPO. However, no benefit has been shown in autologous transplantation, thus anemia remains one of the leading problems in this setting. One possible solution to overcome the effects of this detrimental response could be to administer rHuEPO before autologous transplantation. To verify the hypothesis, 21 multiple myeloma (Epo-MM) cases were assigned to rHuEPO treatment and, as a control group, 42 cases (Ctr-MM), matched for Hb levels and that had not received rHuEPO, were selected. All of them were treated with classical VAD regimen following by cyclophosfamide and melphalan 200 mg/m2 supported by peripheral blood stem cell transplantation (PBSCT). The Epo-MM group was treated with rHuEPO 10,000 IU subcutaneously daily at least 30 days before PBSCT. Median Hb values prior to rHuEPO therapy were 11.8 gr/dL (range 9-14 gr/dL) for Epo-MM and 11.7 gr/dL (range 9 -14 gr/dL) for Ctr-MM. None of them was transfusion dependent. Noteworthy, compared to Ctr-MM, Epo-MM cases were significantly older (median value 59 versus 52 years, p=0.0019) and received a significantly lower amount of CD34+ cells (median value 5x10E6/Kg versus 6x10E6/Kg, p=0.0066). Results showed that Epo-MM cases presented a significantly higher nadir of Hb level (median value Hb 10 gr/dL, range 7.3-14.1, versus Hb 7.7 gr/dL, range 5.9-11.3, p<0.00001), required a significantly lower number of red blood cell transfusions (median value 0, range 0-2, versus 1, range 0-6, p=0.0005) and, interestingly, needed a significantly lesser platelet support (median value 0, range 0-7, versus 2, range 0-16, p=0.0002). These preliminary data indicate that the resistance to rHuEPO, previously documented in the autologous s etting, may be successfully avoided by administering rHuEPO prior to PBSCT. However, its efficacy in the reduction of red cell transfusion requirement should be confirmed in a larger series of patients.
O145 Early post-transplantation vaccination with combination vaccines intended for newborns is safe and effective in children and adolescents
A. Beilken, A. Schrauder, L. Grigull, K. Welte, K. Sykora (Hannover, D)
Objective: Vaccination following allogenic haematopoietic stem cell transplantation (HSCT) should start as early as possible to prevent infectious complications but requires sufficient immune reconstitution for a response to conjugate or polysaccharide vaccines. The optimal time to start vaccination remains to be determined. We studied the safety and effectiveness in BMT patients of 5-or 6 antigen combination vaccines intended for primary immunization in newborns. Study Design: We chose an early vaccination approach starting approximately 4 months following HSCT. In 20 patients, the first vaccination was given between day +123 and +182 (median +140) following allogenic HSCT for malignant (n=15) and nonmalignant (n=5) conditions. The vaccine preparations included antigens of Diphtheria, Tetanus, Polio, Pertussis, Haemophilus influenzae type B (conjugated), and Hepatitis B, as recommended by the German vaccination commission (STIKO). Additionally, a pneumococcal conjugate vaccine (3x) followed by one pneumococcal polysaccharide booster as well as HAV and influenza vaccinations were given. Specific antibody titres were monitored and adverse events as well as serious infections were recorded. Results: Vaccinations were generally well tolerated. Three febrile and two local reactions were noticed, predominantly in older children. It is likely, however, that not all minor adverse events have been reported. There was no activation of GvHD related to vaccination. Titres prior to vaccination on approximately day +100 usually showed antibody protection from routine immunoglobulin prophylaxis following HSCT. After vaccination, all titres monitored on day +200 and one year after HSCT were in the protective range in all but one patient. We documented one pneumococcal septicaemia 11 weeks after the first pneumococcal conjugate vaccination. The boy recovered after antibiotic treatment without further complications. In three adolescent patients transplanted earlier and not included in this study, we had documented infections with HIB (1 septic coxitis and 2 tracheobronchitis). Conclusion: Early vaccination with combination vaccines intended for newborns was safe in all our patients. The higher doses of Diphtheria antigen present in these vaccines did not result in increased toxicity. Antibody titres showed good protection one year after HSCT, making the convenience of combination vaccines available to BMT patients.
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Topically applied recombinant human granulocytemacrophage colony stimulating factor (rhGM-CSF) for oropharyngeal mucositis (OM) in stem cell transplantation recipients: a randomized double-blind placebo-control study D. Valcarcel, M. Sanz, A. Sureda, M. Sala, L. Muñoz, M. Subira, A. Clopes, J. Sierra (Barcelona, E) Oral mucositis (OM) is one of the most frequent side effects of patients receiving high dose chemo/radiotherapy and stem cell transplantation. Mucosal damage is a multistep process involving the release of inflammatory cytokines and DNA damage leading to a breakdown of mucosal barriers and an increased risk of infections. It not only causes pain and makes oral food intake difficult but also produces sleep disorders. We investigated whether daily oral washings with recombinant human granulocytemacrophage colony-stimulating factor (rhGM-CSF) solution improved grade III -IV OM in patients with hematological malignancies undergoing stem cell transplantation. Forty-one consecutive patients [21 males, median age (range) 44 (16-69) years] were prospectively randomized to perform daily mouthwashes either with a 400 mg rhGM-CSF (Molgramostin®, Schering-Plough, AS) solution (group A, n = 18) or with a saline solution (group B, n = 23). The primary end-point was the intensity of OM, as measured daily by the WHO scale, a subjective spontaneous and swallowing-induced pain scale (EVA scale), night rest quality and characteristics of food intake. Secondary end-points were the need for and the duration of parenteral nutrition, oral and intravenous analgesic requirements, incidence of viral or fungal oral infections and development of neutropenic fever. No differences were found between the placebo and GM-CSF treated groups regarding overall duration of OM (12.5 ± 3.4 days in group A vs 11.4 ± 4 days in B), maximum grade (3.5 ± 1.7 days in group A vs 3.6 ± 1.5 days in B), reduction in at least one grade of OM [9 patients (56%) in group A vs 13 patients (68%) in group B], reduction of spontaneous or swallowing-induced pain, improvement in oral food intake, use of parenteral nutrition or use of systemic analgesics. In conclusion, mouth-washings with a 400 mg of rhGM-CSF solution in the established conditions of this protocol do not improve severe OM or its side-effects in hematological patients undergoing stem cell transplantation.
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No role for parenteral glutamine supplementation in autologous stem cell transplant patients: results of a tripleblinded study IGA MZ ÈR 5502/3 R. Pytlik, P. Benes, E. Gregora, M. Pajorková, E. Chocenská, B. Procházka, T. Kozák (Praha, CZ) Background: Glutamine supplementation has been found beneficial for stem-cell transplant recipients in several randomized trials. It was suggested that glutamine can alleviate treatmentrelated mucositis and contribute to immunological recovery. To study its effect on unselected cohort of autologous transplant patients we have conducted a placebo-controlled, triple-blinded study of parenteral glutamine supplementation. Methods: Randomization was stratified according to diagnosis (myeloma vs. others) and even the statistitian did not know patient allocations before the calculations were done. Patients randomized to glutamine arm received 30 g of alanyl-glutamine dipeptide daily (Dipeptiven, Kabi-Fresenius) iv from day +1 to day +14 or to discharge from hospital. Control group received an isonitrogenous glutamine-free standard aminoacid solution. Daily assesment of clinical status, mucositis, (Nebrasca Oral Assesment Score -MUCPEAK, nausea, vomiting and diarrhoe) and blood counts was performed. CD4, CD8, CD19 and CD56 subpopulations of lymphocytes and IgG, IgA and IgM classes of immunoglobulins were measured on admission, on day +14, +28 and +42. Chi-square tests, Student and Spearman correlation tests were performed as appropriate. Results: Forty patients (16 lymphoma, 11 myeloma, 4 solid tumours, 4 multiple sclerosis, 3 CLLs and 2 AMLs) were randomized; 21 into the glutamine and 19 into the placebo arm. There was no laboratory evidence of faster immune recovery in any of the lymphocyte subpopulation or immunoglobuline class with glutamine supplementation. The only clinical benefit of glutamine was less days with diarrhoe (2 v. 4, p = 0.03). On the other hand, glutamine patients had more severe oral mucositis (4 v. 1 day of MUCPEAK >13, p = 0.04), spent more days on opioids (3.5 v. 1 day, p = 0.04) and tended to have more febrile days (2.5 v. 1, p = 0.09), longer hospital stay (13.5 v. 12 days after transplant, p = 0.06), and more relapses (5 v. 1, p = 0.08). This all was transformed to higher costs of supportive care in glutamine group (mean 2426 v. 757 Euro, p = 0.008). The mean cost of glutamine supplementation itself was 710 Euro per patient. Conclusion: The mode and dosage of glutamine administration used in our autologous transplant patients cannot be recommended for routine use. Other schedules (higher dose or oral form of administration) should be evaluated in well-designed experimental trials only.
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Glutamine-enriched parenteral nutrition after autologous peripheral blood stem cell transplantation: effects on immune reconstitution and mucositis N. Piccirillo, S. De Matteis, L. Laurenti, P. Chiusolo, F. Sorà, S. Rutella, S. Cicconi, A. Fiorini, G. D'Onofrio, G. Leone, S. Sica (Rome, I) Glutamine, a nonessential amino acid, has recently received increasing attention because this amino acid becomes essential during stress and catabolic states, including BMT. In fact glutamine seems to modulate immune function, to promote faster intestinal healing and to have trophic effects on the intestine. We designed two randomized clinical trials to evaluate the role of glutamine-enriched parenteral nutrition (GEPN) in patients affected by haematological malignancies submitted to high dose chemotherapy and autologous peripheral blood stem cell transplantation (aPBSCT) or immunoselected CD34+aPBSCT. In the first randomized study, group 1A (12 pts, 7m/5f, median age 37.5y) received Glamin (Fresenius Kabi) 1000 ml/die (a parenteral aminoacidic solution also containing glutamine 20 g) from day +1 after aPBSCT, while group 1B (15 pts, 10m/5f, median age 47y) received a placebo. In the second randomized study, group 2A (10 pts, 5m/5f, median age 31.5y) received Dipeptiven (Fresenius Kabi) 100 ml/die (a parenteral solution containing only glutamine 13.46 g) from day +1 after aPBSCT, while group 2B (11 pts, 8m/3f, median age 49y) received a placebo. Both study groups were comparable for age, sex, diagnosis, conditioning regimen and CD34+/kg cell dose reinfused. There were no significant differences in PMN, platelets, Reticulocyte recovery, length of hospitalization and non-prophylactic antibiotic therapy, fever, sepsis occurrence, transfusional requirements. Statistical analysis showed a difference in lymphocytes recovery: in first study lymphocytes counts >0.5x10e9/L was achieved on day 16,5 (range 10-27) in patients receiving Glamin and on day 29 (range 12-50) in patients receiving placebo, p=0.005; in second study lymphocytes counts >0.5x10e9/L was achieved on day 18 (range 12-22) in patients receiving Dipeptiven and on day 29 (range 12-60) in patients receiving placebo, p=0.009. These differences are maintained when CD4+ subset was analyzed separately. Furthermore all patients undergone GEPN (1A and 2A groups), compared to all patients undergone placebo (1B and 2B groups), showed a significant decrease in mucositis severity peak calculated by DMS (daily mucositis score: sum of signs's and symptoms's daily score) (p=0.025). Thus, in our experience, GEPN is safe and efficacious to improve lymphocytes recovery and, particularly, CD4+ subset, after aPBSCT; further studies are needed to assess clinical benefits of such approach to justify economical impact.
Cellular Therapy
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Characterization of minor histocompatibility antigens on canine hematopoietic precursor cells M. Weber, C. Lange, M. Franz, E. Kremmer, H. Kolb (Munich, D) Minor histocompatibility antigens (mHA) are mainly defined by the following characteristics: they are recognized by T cells, their presentation is restricted to a specific MHC type, they occur with variable phenotype frequencies and they are segregated in a Mendelian fashion. Here we report the in vitro immunization of T cells against mHA in DLA-identical canine littermates and the subsequent characterization of the resulting CTLs. Bone marrow derived dendritic cells were used for the generation of mHA-specific CTLs using co-culture with fresh donor T cells. The ability of immunized CTLs to suppress the growth of hematopoietic precursor cells (HPC) was tested in a Delta-Assay, performed in analogy of the delta culture in the mouse (Muench MO and Moore MA, 1992) using lineage-negative bone marrow as target cells. The target cells were plated in a 96-well plate at decreasing cell numbers ranging from 16.000 to 125 cells per well. The growth of HPC was stimulated by the addition of 20% FCS, 100 ng/ml SCF, 800 U/ml GM-CSF, 2 U/ml Epo, 100 ng/ml IL-3 and 3% allogeneic MLC supernatant. At the start of the Delta Assay irradiated mHA-specific CTLs were added to the wells in a fixed number of 10.000 cells, resulting in a range of effector to target cell ratios from 0.6:1 to 80:1. After 4 days the 3H-thymidine uptake of the target cells was measured and compared to the control. The results showed a highly specific inhibition of HPC-growth in 53% (8/15) analysed DLA-identical littermate combinations, ranging from a HPC-growth inhibition of 30% to 98% compared to the control. In vitro segregation analysis performed in one selected family showed that mHA-specific CTLs were able to recognize HPC from some but not all littermates of the family apart from the stimulator (table 1) whereas HPC from an unrelated animal were not recognized. We further observed one way reactivity in two cases in different dog families. One setting between two male littermates proved the involvement of autosomally-encoded mHA. The other case was showing a one-way reaction of female-derived CTLs against male HPC, strongly indicating the involvement of a Y -chromosome encoded mHA. We have shown an in vitro immunization of CTLs against mHA in DLA-identical canine littermates and shown the heredity of the involved mHA through segregation analysis in one canine family. These mHA in the dog may prove as a valid model for the treatment of leukemia in man by mHA-specific T cells.
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Generation of surviving-specific cytotoxic T-Lymphocytes for the treatment of hematological malignancies M. Zeis, S. Siegel, A. Wagner, P. Dreger, N. Schmitz (Kiel, D) Survivin is a member of the family of inhibitor of apoptosis proteins and is overexpressed in many types of cancer including hematopoietic malignancies. Recently, Survivin-derived peptides were shown to induce CD8+ cytotoxic T lymphocytes (CTL) when presented on dendritic cells (DC). In the current study, we determined whether Survivin-reactive CTL were able to recognize and to kill Survivin-expriming hematological targets. Survivinspecific CTL were generated from leukaphereses products obtained from healthy HLA-A*0201 positive volunteers by incubating T cells with autologous dendritic cells pulsed with DOTAP complexed Survivin-RNA. Survivin-specific CTL lysed HLA-A2+ Survivin + tumor cells including primary lymphoma, acute lymphatic leukemia, multiple myeloma, as well as fresh leukemic blasts from AML patients, indicating that Survivin-derived peptides are naturally processed and presented by tumors. Normal Survivin-negative target cells including CD14+ monocytes and activated B cells were not attacked by Survivin-specific CTL. For the first time, these data show that Survivin-specific CTL are capable of lysing both tumor cell lines and fresh leukemic blasts and thus can be used for specific cellular immunotherapy against several hematological malignancies.
